(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 5.38% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.76%.
Pulmonx's revenue in 2025 is $90,549,000.On average, 2 Wall Street analysts forecast LUNG's revenue for 2025 to be $3,703,250,742, with the lowest LUNG revenue forecast at $3,667,190,040, and the highest LUNG revenue forecast at $3,739,311,444. On average, 2 Wall Street analysts forecast LUNG's revenue for 2026 to be $4,065,080,159, with the lowest LUNG revenue forecast at $4,059,579,374, and the highest LUNG revenue forecast at $4,070,580,944.
In 2027, LUNG is forecast to generate $4,523,275,182 in revenue, with the lowest revenue forecast at $4,519,607,992 and the highest revenue forecast at $4,526,942,372.